

# Diabetes Care

THE JOURNAL OF CLINICAL AND APPLIED RESEARCH AND EDUCATION

March 2015 Volume 38, Number 3

## In This Issue

341 In This Issue of *Diabetes Care*






## Commentaries

- 343 Responding to the Challenges of Primary Diabetes Care Through the National Diabetes Education Program  
*K.A. Peterson, M.T. Brown, and E. Warren-Boulton*
- 345 Gestational Diabetes Mellitus and the Offspring—Jack and Jill Are Different Still  
*H. Murphy and S. Finer*

## Profiles in Progress

- 347 Saul Genuth, MD: Clinical Researcher and Leader in Developing Modern Diabetes Treatment  
*A.M. Jacobson and D.M. Nathan*

## Evolving Tactics With Inhibition of Sodium–Glucose Cotransporters

- 352 SGLT2 Inhibitors: The Latest “New Kids on the Block”!  
*W.T. Cefalu and M.C. Riddle*
- 355  Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study  
*L.A. Leiter, K.-H. Yoon, P. Arias, G. Langslet, J. Xie, D.A. Balis, D. Millington, F. Vercrussey, W. Canovatchel, and G. Meininger*
- 365  Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial  
*S. Matthaai, K. Bowering, K. Rohwedder, A. Grohl, and S. Parikh, for the Study 05 Group*
- 373 Where Does Combination Therapy With an SGLT2 Inhibitor Plus a DPP-4 Inhibitor Fit in the Management of Type 2 Diabetes?  
*M. Abdul-Ghani*
- 376 Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin  
*J. Rosenstock, L. Hansen, P. Zee, Y. Li, W. Cook, B. Hirshberg, and N. Iqbal*
- 384  Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin  
*R.A. DeFronzo, A. Lewin, S. Patel, D. Liu, R. Kaste, H.J. Woerle, and U.C. Broedl*
- 394  Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes  
*A. Lewin, R.A. DeFronzo, S. Patel, D. Liu, R. Kaste, H.J. Woerle, and U.C. Broedl*
- 403  Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes  
*B. Neal, V. Perkovic, D. de Zeeuw, K.W. Mahaffey, G. Fulcher, K. Ways, M. Desai, W. Shaw, G. Capuano, M. Alba, J. Jiang, F. Vercrussey, G. Meininger, and D. Matthews, on behalf of the CANVAS Trial Collaborative Group*

412



Exploring the Potential of the SGLT2 Inhibitor Dapagliflozin in Type 1 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Pilot Study  
*R.R. Henry, J. Rosenstock, S. Edelman, S. Mudaliar, A.-G. Chalamandaris, S. Kasichayanula, A. Bogle, N. Iqbal, J. List, and S.C. Griffen*

→ 420

Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension  
*I. Tikkanen, K. Narko, C. Zeller, A. Green, A. Salsali, U.C. Broedl, and H.J. Woerle, on behalf of the EMPA-REG BP Investigators*

429

Blood Pressure Reduction: An Added Benefit of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes  
*C. Majewski and G.L. Bakris*

431

Greater Dose-Ranging Effects on A1C Levels Than on Glucosuria With LX4211, a Dual Inhibitor of SGLT1 and SGLT2, in Patients With Type 2 Diabetes on Metformin Monotherapy  
*J. Rosenstock, W.T. Cefalu, P. Lapuerta, B. Zambrowicz, I. Ogbaa, P. Banks, and A. Sands*

## Clinical Care/Education/Nutrition/Psychosocial Research

- 439 PCSK7 Genotype Modifies Effect of a Weight-Loss Diet on 2-Year Changes of Insulin Resistance: The POUNDS LOST Trial  
*T. Huang, J. Huang, Q. Qi, Y. Li, G.A. Bray, J. Rood, F.M. Sacks, and L. Qi*
- 445 Mild Gestational Diabetes Mellitus and Long-Term Child Health  
*M.B. Landon, M.M. Rice, M.W. Varner, B.M. Casey, U.M. Reddy, R.J. Wapner, D.J. Rouse, J.R. Biggio Jr., J.M. Thorp, E.K. Chien, G. Saade, A.M. Peaceman, S.C. Blackwell, and J.P. VanDorsten, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units (MFMU) Network*
- 453 Risks of Psychiatric Disorders and Suicide Attempts in Children and Adolescents With Type 1 Diabetes: A Population-Based Cohort Study  
*A. Butwicka, L. Frisén, C. Almqvist, B. Zethelius, and P. Lichtenstein*

## Epidemiology/Health Services Research

- 460 Life Years Lost and Lifetime Health Care Expenditures Associated With Diabetes in the U.S., National Health Interview Survey, 1997–2000  
*M.-Y.M. Leung, L.M. Pollack, G.A. Colditz, and S.-H. Chang*
- 469 How Do People With Diabetes Describe Their Experiences in Primary Care? Evidence From 85,760 Patients With Self-reported Diabetes From the English General Practice Patient Survey  
*C.A.M. Paddison, C.L. Saunders, G.A. Abel, R.A. Payne, A.I. Adler, J.P. Gruffy, and M.O. Roland*
- 476 Prevalence of Detectable C-Peptide According to Age at Diagnosis and Duration of Type 1 Diabetes  
*A.K. Davis, S.N. DuBose, M.J. Haller, K.M. Miller, L.A. DiMeglio, K.E. Bethin, R.S. Goland, E.M. Greenberg, D.R. Liljenquist, A.J. Ahmann, S.M. Marcovina, A.L. Peters, R.W. Beck, and C.J. Greenbaum, for the T1D Exchange Clinic Network*
- 482 Trends in Diabetes Incidence: The Framingham Heart Study  
*T.M. Abraham, K.M. Pencina, M.J. Pencina, and C.S. Fox*
- 488 Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals  
*G.P. Leese, I.M. Stratton, M. Land, M.O. Bachmann, C. Jones, P. Scanlon, H.C. Looker, and B. Ferguson, on behalf of the Four Nations Diabetic Retinopathy Screening Study Group*

Keep up with the latest information for *Diabetes Care* and other ADA titles via Facebook ([/ADAJournals](#)) and Twitter ([@ADA\\_Journals](#)).

All articles in *Diabetes Care* are available online at [diabetes.org/diabetescare](http://diabetes.org/diabetescare). Cover articles (➡) and ADA Statements are available free of charge. Each cover article is accompanied by a free online slide set that includes a summary of the article's key points and conclusions as well as associated tables and figures. Other articles are available free to print subscribers or can be purchased as e-prints or reprints.

Icons shown below appear on the first page of an article if more information is available online.



Free Article



Slide Set



Podcast



Supplementary Data



Companion Article



Video

ADA's Diabetes Core Update podcast is available at [diabetesjournals.org](http://diabetesjournals.org) and through iTunes.

- 495** The Risk of Colorectal Cancer in Patients With Type 2 Diabetes: Associations With Treatment Stage and Obesity  
*P.J.H.L. Peeters, M.T. Bazelier, H.G.M. Leufkens, F. de Vries, and M.L. De Bruin*

### Emerging Technologies and Therapeutics

- 503** Pharmacokinetics and Pharmacodynamics of Insulin Glargine Given in the Evening as Compared With in the Morning in Type 2 Diabetes  
*F. Porcellati, P. Lucidi, P. Cioli, P. Candeloro, A. Marinelli Andreoli, S. Marzotti, M. Ambrogio, G.B. Bolli, and C.G. Fanelli*

### Pathophysiology/Complications

- 513** Tyrosine Phosphatase-Related Islet Antigen 2<sub>(256–760)</sub> Autoantibodies, the Only Marker of Islet Autoimmunity That Increases by Increasing the Degree of BMI in Obese Subjects With Type 2 Diabetes  
*R. Buzzetti, M. Spoletini, S. Zampetti, G. Campagna, L. Marandola, F. Panimolle, F. Dotto, and C. Tiberti, for the NIRAD Study Group (NIRAD 8)*

### Cardiovascular and Metabolic Risk

- 521** Serum 25-Hydroxyvitamin D: A Predictor of Macrovascular and Microvascular Complications in Patients With Type 2 Diabetes  
*M. Herrmann, D.R. Sullivan, A.-S. Veillard, T. McCorquodale, I.R. Straub, R. Scott, M. Laakso, D. Topliss, A.J. Jenkins, S. Blankenberg, A. Burton, and A.C. Keech, for the FIELD Study Investigators*

### Meta-analysis

- 529** Sleep Duration and Risk of Type 2 Diabetes: A Meta-analysis of Prospective Studies  
*Z. Shan, H. Ma, M. Xie, P. Yan, Y. Guo, W. Bao, Y. Rong, C.L. Jackson, F.B. Hu, and L. Liu*

### Erratum

- 538** Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). *Diabetes Care* 2014;37:2149–2158  
*M. Nauck, R.S. Weinstock, G.E. Umpierrez, B. Guerci, Z. Skrivaneck, and Z. Milicevic*

### Issues and Events

- 539** Issues and Events

### e-Letters – Observations

- e32** Effect of Bariatric Surgery Versus Intensive Medical Management on Diabetic Ophthalmic Outcomes  
*R.P. Singh, R. Gans, S.R. Kashyap, R. Bedi, K. Wolski, S.A. Brethauer, S.E. Nissen, D.L. Bhatt, and P. Schauer*
- e34** Blinded Continuous Glucose Monitoring During Yom Kippur Fasting in Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion Therapy  
*M. Metzger, L. Lederhendler, and A. Corcos*
- e36** Retinal Thinning as a Marker of Disease Progression in Patients With Wolfram Syndrome  
*A. Zmyslowska, W. Fendler, A. Niwald, M. Ludwikowska-Pawlowska, M. Borowiec, K. Antosik, A. Szadkowska, and W. Mlynarski*

- e38** Remission of Severe Neonatal Diabetes With Very Early Sulfonylurea Treatment  
*B.A. Marshall, R.P. Green, J. Wambach, N.H. White, M.S. Remedi, and C.G. Nichols*

### e-Letters – Comments and Responses

- e40** Comment on Duran et al. Introduction of IADPSG Criteria for the Screening and Diagnosis of Gestational Diabetes Mellitus Results in Improved Pregnancy Outcomes at a Lower Cost in a Large Cohort of Pregnant Women: The St. Carlos Gestational Diabetes Study. *Diabetes Care* 2014;37:2442–2450  
*R. Rodríguez-Gutiérrez and J.G. González-González*
- e41** Response to Comment on Duran et al. Introduction of IADPSG Criteria for the Screening and Diagnosis of Gestational Diabetes Mellitus Results in Improved Pregnancy Outcomes at a Lower Cost in a Large Cohort of Pregnant Women: The St. Carlos Gestational Diabetes Study. *Diabetes Care* 2014;37:2442–2450  
*A. Duran, M.J. Torrejón, I. Runkle, and A.L. Calle-Pascual*
- e43** Comment on Liu et al. Latent Autoimmune Diabetes in Adults With Low-Titer GAD Antibodies: Similar Disease Progression With Type 2 Diabetes: A Nationwide, Multicenter Prospective Study (LADA China Study 3). *Diabetes Care* 2015;38:16–21  
*V.N. Shah and L. Yu*
- e44** Response to Comment on Liu et al. Latent Autoimmune Diabetes in Adults With Low-Titer GAD Antibodies: Similar Disease Progression With Type 2 Diabetes: A Nationwide, Multicenter Prospective Study (LADA China Study 3). *Diabetes Care* 2015;38:16–21  
*X. Li, L. Liu, Y. Xiang, G. Huang, R.D. Leslie, and Z. Zhou*
- e45** Comment on O'Connor et al. Randomized Trial of Telephone Outreach to Improve Medication Adherence and Metabolic Control in Adults With Diabetes. *Diabetes Care* 2014;37:3317–3324  
*I.D. Blackburn, J.S. Furler, J.D. Best, and D. Young*
- e46** Response to Comment on O'Connor et al. Randomized Trial of Telephone Outreach to Improve Medication Adherence and Metabolic Control in Adults With Diabetes. *Diabetes Care* 2014;37:3317–3324  
*P.J. O'Connor, J.A. Schmittiel, R.D. Pathak, R.I. Harris, and K.M. Newton*
- e47** Comment on Steck et al. Early Hyperglycemia Detected by Continuous Glucose Monitoring in Children at Risk for Type 1 Diabetes. *Diabetes Care* 2014;37:2031–2033  
*D. Brancato and V. Provenzano*
- e48** Response to Comment on Steck et al. Early Hyperglycemia Detected by Continuous Glucose Monitoring in Children at Risk for Type 1 Diabetes. *Diabetes Care* 2014;37:2031–2033  
*A.K. Steck, F. Dong, I. Taki, M. Hoffman, G.J. Klingensmith, and M.J. Rewers*
- e49** Comment on Tovote et al. Individual Mindfulness-Based Cognitive Therapy and Cognitive Behavior Therapy for Treating Depressive Symptoms in Patients With Diabetes: Results of a Randomized Controlled Trial. *Diabetes Care* 2014;37:2427–2434  
*V.Y. Womack and M.R. Carnethon*